Developer docs
API playgroundTry for free, no card

Search company profiles

Lucida Medical

Full company profile

uuid0002l61

Namestring
Lucida Medical
Legal namestring
Lucida Medical Ltd
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Lucida Medical is a Cambridge-based healthtech company founded in 2019 that develops Pi (Prostate Intelligence), a CE-marked AI medical-device software for prostate cancer detection from MRI scans. Pi uses deep learning models to automatically segment the prostate and suspicious lesions, generate patient- and lesion-level risk scores, and produce structured template reports; the latest release integrates PSA density and PI-RADS assessments into a single combined risk score with an accept-or-revise segmentation workflow. The core technology was trained and externally validated on 1,046+ NHS patient MRI scans across 8 UK NHS trusts, demonstrating 95% sensitivity and 67% specificity (AUC 0.91) for clinically significant prostate cancer across multiple scanner vendors, models, and field strengths.

The company monetises Pi via subscription-based SaaS licensing to NHS hospital trusts and Cancer Alliances in the UK, with international reach through PACS/integrator platform partnerships (Sectra Amplifier Marketplace, Blackford, DeepC, Ferrum Health) and regional distributors (K2Ai in Israel, HealthCare Konnect in Switzerland/North Africa, Aplicaciones Tecnológicas in Spain). It serves radiologists, urologists, and multidisciplinary cancer teams, addressing radiologist shortages (30% UK shortfall, projected to 40% by 2028), diagnostic delays (2–3 months), missed cancers on MRI (up to 10%), and unnecessary biopsies (~20% reduction potential with Pi). Pi integrates with PACS via the GE Healthcare Edison Open AI Orchestrator and exports lesion segmentations in RTSTRUCT format for fusion-biopsy systems such as Koelis Trinity.

Lucida Medical has raised approximately £11.25M+ across grants and equity rounds from investors including IW Capital, XTX Ventures, Macmillan Cancer Support, SBRI Healthcare, and Innovate UK. The product is CE-certified in the UK/EU and is pursuing US FDA approval funded by the March 2026 round. The leadership team combines AI/medical-device engineering depth with elite clinical credibility, including Prof Anwar Padhani (Co-Chair of the PI-RADS Steering Committee) as CMO, Prof Evis Sala as Co-Founder and Medical Advisory Board Chair, and Dr David Tuch (ex-Novartis, ex-GE Healthcare) as Board Chair.

Short descriptiontext

Lucida Medical is a Cambridge-based healthtech company that develops Pi, a CE-marked AI medical-device software for prostate cancer detection from MRI scans, sold via SaaS subscriptions to NHS trusts and international health systems through direct sales and PACS-integrator partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI medical imaging software, prostate cancer diagnostics, MRI analysis platform, radiology decision support, medical device SaaS
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Radiology Diagnostics Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1AI Diagnostic Software Subscription (Pi SaaS)
TypeSubscription Recurring
Description

Subscription-based SaaS licensing of the Pi (Prostate Intelligence) AI diagnostic software to NHS hospitals, health systems, and international healthcare providers. CE-certified and deployed across NHS hospitals in the UK and EU. The software is offered through direct enterprise agreements with NHS trusts, through PACS/integrator partner platforms (Sectra, Blackford, DeepC, Ferrum), and through regional distribution partners (K2Ai, HealthCare Konnect, Aplicaciones Tecnológicas). Pricing is not publicly disclosed — quote-based enterprise sales. NHS procurement cycles and Cancer Alliance implementation programs support recurring revenue dynamics.

lucidamedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Pi (Prostate Intelligence)
Description

AI-powered diagnostic software for prostate cancer detection from MRI scans. CE-certified medical device that provides automated prostate and lesion segmentation, risk scores, and clinical decision support for radiologists.

lucidamedical.com
Core offering1 text field

Lucida Medical develops Pi (Prostate Intelligence), a CE-marked AI medical device software that analyzes prostate MRI scans to detect and diagnose clinically significant prostate cancer. The software performs automated prostate and lesion segmentation, generates risk scores, produces visual heat maps, and creates structured template reports that support radiologists and urologists in clinical decision-making across the prostate cancer diagnostic pathway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 95% sensitivity for clinically significant prostate cancer (Gleason grade >=3+4) on external NHS validation data
+9 more records
Product overview1 text field

Lucida Medical offers a single unified product, Pi (Prostate Intelligence), an AI-powered medical device software for prostate cancer diagnosis from MRI scans. Pi analyzes prostate MRI to automatically segment the prostate organ and suspicious lesions, generate risk scores, and produce template reports that support radiologists in detecting clinically significant prostate cancer or identifying patients who can avoid unnecessary biopsies. The system has been validated across multiple NHS hospitals and is CE-marked for use in the UK and EU. Recent updates integrate PSA density and PI-RADS assessments for enhanced clinical decision support.

Product and service2 records
1Pi (Prostate Intelligence)
CategoryAI Radiology Diagnostics Software
Description

CE-marked AI medical device software that analyzes prostate MRI scans to assist prostate cancer diagnosis. Pi automatically segments the prostate and suspicious lesions, generates risk scores, and produces template reports to help radiologists detect clinically significant prostate cancer or rule out patients who do not need further investigation. Designed for radiologists, urologists, and NHS hospital trusts.

2Pi Next Generation Software Update
CategoryAI Radiology Diagnostics Software
Description

Updated version of the Pi software platform that introduces an integrated risk score combining AI risk scores, PSA density, and PI-RADS assessments, along with an accept-or-revise workflow for AI-generated lesion segmentations before PACS export.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-01
Description

Koelis, led by founder and CEO Dr Antoine Leroy, provides the Trinity MRI/Ultrasound fusion guidance system using proprietary Organ Based Tracking technology. Combined Pi AI prostate MRI analysis with Koelis 3D ultrasound fusion guidance for the first integrated prostate fusion biopsy at Hampshire Hospitals NHS Foundation Trust. The integration streamlines the workflow between radiology and urology.

Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Healthcare technology provider based in Israel. Strategic partnership to integrate Lucida Medical's AI solution into clinical workflows in Israeli healthcare institutions. K2Ai's CEO Kfir Kaper stated the partnership aligns with their mission to bring physicians access to the most innovative technologies worldwide. K2Ai works closely with healthcare institutions across Israel to deploy Pi at key stages of the diagnostic process.

Strategic tierKeyTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-07-01
Description

Independent evaluator engaged to assess the clinical performance and health economic impact of Pi deployment in NHS hospitals under the SBRI Healthcare program. Dr Hugh Harvey, Managing Director and Project Lead at Hardian Health, commented on the potential for earlier diagnosis and cost savings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Academic partner and spin-out origin. Lucida Medical was co-founded in 2019 by Prof Evis Sala (then at University of Cambridge). Ongoing research collaboration including the PAIR-1 study and expansion of the Pi AI platform for prostate cancer care. Also a partner in the ReIMAGINE prostate imaging trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

NHS trust and primary clinical research partner. Led the PAIR-1 study (Chief Investigator Dr Aarti Shah, Sponsor role). Ongoing clinical collaboration including fusion biopsy integration project, active surveillance support, and pilot site for Pi deployment. Professor Richard Hindley (Consultant Urologist) and Dr Aarti Shah (Consultant Radiologist) are key clinical investigators.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

International medical imaging IT and cybersecurity company. Distribution agreement for Lucida Pi to be offered through the Sectra Amplifier Marketplace, greatly expanding availability to hospitals globally. Separate partnership for enterprise imaging integration supporting the fusion biopsy project at Hampshire Hospitals NHS Foundation Trust.

Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

AI platform providing healthcare professionals access to 120+ AI solutions. Integrating Lucida Medical's Pi into the Blackford Platform to offer healthcare providers advanced tools for prostate MRI analysis.

Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

AI-focused operating system that brings multiple AI solutions including Pi under one intuitive user interface, broadening market reach for Lucida Medical.

Strategic tierKeyTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

AI platform for medical imaging covering a range of specialties including Pi, operating in the USA and internationally, providing additional channel for US and global market access.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Medical software distributor focusing on Switzerland and North Africa. Offers local support and a shared platform to aid clinical workflows for Pi deployment in these regions.

11Aplicaciones Tecnológicas
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Spanish distributor (ATFISICA) offering quality AI solutions to help radiologists in clinical diagnostic imaging, building a comprehensive portfolio covering most organs and image acquisition techniques, with national technical support service for Pi in Spain.

lucidamedical.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Selected from 350 applicants to be one of 6 companies in GE Healthcare's Edison Accelerator programme in 2021. Worked with GE Healthcare's Edison Open AI Orchestrator to integrate Pi with EMRAD's radiology information system, PACS, and viewer, demonstrating seamless integration into radiologist workflows with data remaining inside NHS firewall.

13EMRAD (East Midlands Imaging Network)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Pioneering organisation pooling radiology resources amongst 8 NHS trusts from across the East Midlands. Partnered with Lucida Medical and GE Healthcare for the Edison Accelerator service evaluation project, providing multi-site NHS data environment for Pi workflow integration testing.

lucidamedical.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based AI company developing prostate cancer diagnostics and treatment planning (iQuest AI biopsy platform and focal laser ablation). Directly competes with Lucida in AI-enabled prostate cancer detection and is pursuing FDA-cleared prostate cancer AI — a primary US competitive threat.

TypeDirect peer
Description

US-based company developing multimodal AI biomarkers for prostate cancer (ArteraAI Prostate Test) that integrates clinical and pathology data to predict treatment outcomes. A direct competitor in prostate cancer AI decision support, with established US payer reimbursement.

TypeDirect peer
Description

France-based developer of the Trinity MRI/ultrasound fusion biopsy system with proprietary Organ-Based Tracking. Already a Lucida technology partner, but its Prostate Suite and AI-driven biopsy planning overlap directly with Pi's biopsy-planning workflow on the same target customers (urologists, hospitals).

TypeDirect peer
Description

Spain-headquartered medical imaging AI company with a portfolio of radiology AI tools including prostate MRI analysis. Comparable as a European-based imaging AI vendor selling multi-modality AI into NHS and EU hospitals via PACS integrator channels.

TypeEmerging player
Description

AI company focused on digital pathology and cancer diagnostics, with FDA-authorized prostate cancer detection products. An emerging player with partial overlap — both target prostate cancer AI, but Paige's primary strength is pathology rather than MRI imaging.

TypeBroad incumbent
Description

Global imaging vendor with AI-Rad Companion platform including prostate MRI capabilities, embedded across a vast installed base of hospital PACS and MRI scanners. A broad incumbent whose bundled AI offerings compete with best-of-breed tools like Pi on procurement decisions.

TypeBroad incumbent
Description

Lucida's integration partner (Edison Open AI Orchestrator) and a broad incumbent selling radiology AI to health systems globally. Competes by offering its own multi-organ AI portfolio and Edison ecosystem, potentially displacing independent vendors like Lucida over time.

TypeBroad incumbent
Description

Global imaging and informatics vendor offering radiology AI orchestration platforms and prostate imaging solutions to large hospital networks. Comparable broad incumbent competing for the same enterprise AI procurement budgets.

TypeEmerging player
Description

AI radiology subsidiary of RadNet focused on prostate, breast, and lung cancer detection from medical imaging. An emerging player with overlapping prostate AI focus and a US delivery model that may compete for the same hospital and imaging-center customers.

TypeEmerging player
Description

Israel-based AI company specializing in cancer diagnostics (primarily digital pathology) with deployments across NHS and EU hospitals. An emerging player with adjacent cancer-AI capability, similar European health-system go-to-market, and overlapping investor ecosystems.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucida Medical

AI Radiology Diagnostics Softwarelucidamedical.com

Lucida Medical is a Cambridge-based healthtech company that develops Pi, a CE-marked AI medical-device software for prostate cancer detection from MRI scans, sold via SaaS subscriptions to NHS trusts and international health systems through direct sales and PACS-integrator partnerships.

What Lucida Medical does

Lucida Medical is a Cambridge-based healthtech company founded in 2019 that develops Pi (Prostate Intelligence), a CE-marked AI medical-device software for prostate cancer detection from MRI scans. Pi uses deep learning models to automatically segment the prostate and suspicious lesions, generate patient- and lesion-level risk scores, and produce structured template reports; the latest release integrates PSA density and PI-RADS assessments into a single combined risk score with an accept-or-revise segmentation workflow. The core technology was trained and externally validated on 1,046+ NHS patient MRI scans across 8 UK NHS trusts, demonstrating 95% sensitivity and 67% specificity (AUC 0.91) for clinically significant prostate cancer across multiple scanner vendors, models, and field strengths.

The company monetises Pi via subscription-based SaaS licensing to NHS hospital trusts and Cancer Alliances in the UK, with international reach through PACS/integrator platform partnerships (Sectra Amplifier Marketplace, Blackford, DeepC, Ferrum Health) and regional distributors (K2Ai in Israel, HealthCare Konnect in Switzerland/North Africa, Aplicaciones Tecnológicas in Spain). It serves radiologists, urologists, and multidisciplinary cancer teams, addressing radiologist shortages (30% UK shortfall, projected to 40% by 2028), diagnostic delays (2–3 months), missed cancers on MRI (up to 10%), and unnecessary biopsies (~20% reduction potential with Pi). Pi integrates with PACS via the GE Healthcare Edison Open AI Orchestrator and exports lesion segmentations in RTSTRUCT format for fusion-biopsy systems such as Koelis Trinity.

Lucida Medical has raised approximately £11.25M+ across grants and equity rounds from investors including IW Capital, XTX Ventures, Macmillan Cancer Support, SBRI Healthcare, and Innovate UK. The product is CE-certified in the UK/EU and is pursuing US FDA approval funded by the March 2026 round. The leadership team combines AI/medical-device engineering depth with elite clinical credibility, including Prof Anwar Padhani (Co-Chair of the PI-RADS Steering Committee) as CMO, Prof Evis Sala as Co-Founder and Medical Advisory Board Chair, and Dr David Tuch (ex-Novartis, ex-GE Healthcare) as Board Chair.

Lucida Medical firmographics

Firmographics
Name
Lucida Medical
Legal name
Lucida Medical Ltd
Website
https://lucidamedical.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Lucida Medical is a Cambridge-based healthtech company that develops Pi, a CE-marked AI medical-device software for prostate cancer detection from MRI scans, sold via SaaS subscriptions to NHS trusts and international health systems through direct sales and PACS-integrator partnerships.
Ownership category
akta.pro rank

Lucida Medical industry classification

Industry
Product category
AI Radiology Diagnostics Software
NAICS
Software Publishers (5132)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • AI medical imaging software
  • Prostate cancer diagnostics
  • MRI analysis platform
  • Radiology decision support
  • Medical device SaaS

Where Lucida Medical is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Lucida Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. AI Diagnostic Software Subscription (Pi SaaS): Subscription-based SaaS licensing of the Pi (Prostate Intelligence) AI diagnostic software to NHS hospitals, health systems, and international healthcare providers. CE-certified and deployed across NHS hospitals in the UK and EU. The software is offered through direct enterprise agreements with NHS trusts, through PACS/integrator partner platforms (Sectra, Blackford, DeepC, Ferrum), and through regional distribution partners (K2Ai, HealthCare Konnect, Aplicaciones Tecnológicas). Pricing is not publicly disclosed — quote-based enterprise sales. NHS procurement cycles and Cancer Alliance implementation programs support recurring revenue dynamics.

Go-to-market motion2 records

Distribution channels8 records

Marketing channels6 records

Lucida Medical product offering

Product offering

Core offering

Lucida Medical develops Pi (Prostate Intelligence), a CE-marked AI medical device software that analyzes prostate MRI scans to detect and diagnose clinically significant prostate cancer. The software performs automated prostate and lesion segmentation, generates risk scores, produces visual heat maps, and creates structured template reports that support radiologists and urologists in clinical decision-making across the prostate cancer diagnostic pathway.

Product overview

Lucida Medical offers a single unified product, Pi (Prostate Intelligence), an AI-powered medical device software for prostate cancer diagnosis from MRI scans. Pi analyzes prostate MRI to automatically segment the prostate organ and suspicious lesions, generate risk scores, and produce template reports that support radiologists in detecting clinically significant prostate cancer or identifying patients who can avoid unnecessary biopsies. The system has been validated across multiple NHS hospitals and is CE-marked for use in the UK and EU. Recent updates integrate PSA density and PI-RADS assessments for enhanced clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

  • Pi (Prostate Intelligence): AI-powered diagnostic software for prostate cancer detection from MRI scans. CE-certified medical device that provides automated prostate and lesion segmentation, risk scores, and clinical decision support for radiologists.

Products and services

  • Pi (Prostate Intelligence) CE-marked AI medical device software that analyzes prostate MRI scans to assist prostate cancer diagnosis. Pi automatically segments the prostate and suspicious lesions, generates risk scores, and produces template reports to help radiologists detect clinically significant prostate cancer or rule out patients who do not need further investigation. Designed for radiologists, urologists, and NHS hospital trusts.
  • Pi Next Generation Software Update Updated version of the Pi software platform that introduces an integrated risk score combining AI risk scores, PSA density, and PI-RADS assessments, along with an accept-or-revise workflow for AI-generated lesion segmentations before PACS export.

Quantifiable outcome

  • 95% sensitivity for clinically significant prostate cancer (Gleason grade >=3+4) on external NHS validation data
  • +9 more outcomes

Companies that use Lucida Medical

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Lucida Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability5 records

Feature6 records

Lucida Medical partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, important, key and regional.

  • KoeliscoreTechnology or Integration · 1 November 2025Koelis, led by founder and CEO Dr Antoine Leroy, provides the Trinity MRI/Ultrasound fusion guidance system using proprietary Organ Based Tracking technology. Combined Pi AI prostate MRI analysis with Koelis 3D ultrasound fusion guidance for the first integrated prostate fusion biopsy at Hampshire Hospitals NHS Foundation Trust. The integration streamlines the workflow between radiology and urology.
  • K2AiimportantStrategic or Co-development Partner · 1 November 2025Healthcare technology provider based in Israel. Strategic partnership to integrate Lucida Medical's AI solution into clinical workflows in Israeli healthcare institutions. K2Ai's CEO Kfir Kaper stated the partnership aligns with their mission to bring physicians access to the most innovative technologies worldwide. K2Ai works closely with healthcare institutions across Israel to deploy Pi at key stages of the diagnostic process.
  • Hardian HealthkeyImplementation/ SI/ Consulting Partner · 1 July 2025Independent evaluator engaged to assess the clinical performance and health economic impact of Pi deployment in NHS hospitals under the SBRI Healthcare program. Dr Hugh Harvey, Managing Director and Project Lead at Hardian Health, commented on the potential for earlier diagnosis and cost savings.
  • University of CambridgecoreStrategic or Co-development Partner · 1 February 2024Academic partner and spin-out origin. Lucida Medical was co-founded in 2019 by Prof Evis Sala (then at University of Cambridge). Ongoing research collaboration including the PAIR-1 study and expansion of the Pi AI platform for prostate cancer care. Also a partner in the ReIMAGINE prostate imaging trial.
  • Hampshire Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner · 1 January 2024NHS trust and primary clinical research partner. Led the PAIR-1 study (Chief Investigator Dr Aarti Shah, Sponsor role). Ongoing clinical collaboration including fusion biopsy integration project, active surveillance support, and pilot site for Pi deployment. Professor Richard Hindley (Consultant Urologist) and Dr Aarti Shah (Consultant Radiologist) are key clinical investigators.
  • SectracoreChannel Partner/ Reseller/ Distributor · 1 January 2024International medical imaging IT and cybersecurity company. Distribution agreement for Lucida Pi to be offered through the Sectra Amplifier Marketplace, greatly expanding availability to hospitals globally. Separate partnership for enterprise imaging integration supporting the fusion biopsy project at Hampshire Hospitals NHS Foundation Trust.
  • BlackfordkeyChannel Partner/ Reseller/ Distributor · 1 January 2024AI platform providing healthcare professionals access to 120+ AI solutions. Integrating Lucida Medical's Pi into the Blackford Platform to offer healthcare providers advanced tools for prostate MRI analysis.
  • DeepCkeyChannel Partner/ Reseller/ Distributor · 1 January 2024AI-focused operating system that brings multiple AI solutions including Pi under one intuitive user interface, broadening market reach for Lucida Medical.
  • Ferrum HealthkeyChannel Partner/ Reseller/ Distributor · 1 January 2024AI platform for medical imaging covering a range of specialties including Pi, operating in the USA and internationally, providing additional channel for US and global market access.
  • HealthCare KonnectregionalChannel Partner/ Reseller/ Distributor · 1 January 2024Medical software distributor focusing on Switzerland and North Africa. Offers local support and a shared platform to aid clinical workflows for Pi deployment in these regions.
  • Aplicaciones TecnológicasregionalChannel Partner/ Reseller/ Distributor · 1 January 2024Spanish distributor (ATFISICA) offering quality AI solutions to help radiologists in clinical diagnostic imaging, building a comprehensive portfolio covering most organs and image acquisition techniques, with national technical support service for Pi in Spain.
  • GE Healthcare (Edison Accelerator)coreTechnology or Integration · 1 January 2021Selected from 350 applicants to be one of 6 companies in GE Healthcare's Edison Accelerator programme in 2021. Worked with GE Healthcare's Edison Open AI Orchestrator to integrate Pi with EMRAD's radiology information system, PACS, and viewer, demonstrating seamless integration into radiologist workflows with data remaining inside NHS firewall.
  • EMRAD (East Midlands Imaging Network)coreStrategic or Co-development Partner · 1 January 2021Pioneering organisation pooling radiology resources amongst 8 NHS trusts from across the East Midlands. Partnered with Lucida Medical and GE Healthcare for the Edison Accelerator service evaluation project, providing multi-site NHS data environment for Pi workflow integration testing.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Lucida Medical competitors and assessment

Company assessment

Direct peers

  • Avenda Health: US-based AI company developing prostate cancer diagnostics and treatment planning (iQuest AI biopsy platform and focal laser ablation). Directly competes with Lucida in AI-enabled prostate cancer detection and is pursuing FDA-cleared prostate cancer AI — a primary US competitive threat.
  • ArteraAI: US-based company developing multimodal AI biomarkers for prostate cancer (ArteraAI Prostate Test) that integrates clinical and pathology data to predict treatment outcomes. A direct competitor in prostate cancer AI decision support, with established US payer reimbursement.
  • KOELIS: France-based developer of the Trinity MRI/ultrasound fusion biopsy system with proprietary Organ-Based Tracking. Already a Lucida technology partner, but its Prostate Suite and AI-driven biopsy planning overlap directly with Pi's biopsy-planning workflow on the same target customers (urologists, hospitals).
  • Quibim: Spain-headquartered medical imaging AI company with a portfolio of radiology AI tools including prostate MRI analysis. Comparable as a European-based imaging AI vendor selling multi-modality AI into NHS and EU hospitals via PACS integrator channels.

Emerging players

  • Paige.AI: AI company focused on digital pathology and cancer diagnostics, with FDA-authorized prostate cancer detection products. An emerging player with partial overlap — both target prostate cancer AI, but Paige's primary strength is pathology rather than MRI imaging.
  • DeepHealth (RadNet): AI radiology subsidiary of RadNet focused on prostate, breast, and lung cancer detection from medical imaging. An emerging player with overlapping prostate AI focus and a US delivery model that may compete for the same hospital and imaging-center customers.
  • Ibex Medical Analytics: Israel-based AI company specializing in cancer diagnostics (primarily digital pathology) with deployments across NHS and EU hospitals. An emerging player with adjacent cancer-AI capability, similar European health-system go-to-market, and overlapping investor ecosystems.

Broad incumbents

  • Siemens Healthineers (AI-Rad Companion): Global imaging vendor with AI-Rad Companion platform including prostate MRI capabilities, embedded across a vast installed base of hospital PACS and MRI scanners. A broad incumbent whose bundled AI offerings compete with best-of-breed tools like Pi on procurement decisions.
  • GE Healthcare (Edison): Lucida's integration partner (Edison Open AI Orchestrator) and a broad incumbent selling radiology AI to health systems globally. Competes by offering its own multi-organ AI portfolio and Edison ecosystem, potentially displacing independent vendors like Lucida over time.
  • Philips (IntelliSpace AI): Global imaging and informatics vendor offering radiology AI orchestration platforms and prostate imaging solutions to large hospital networks. Comparable broad incumbent competing for the same enterprise AI procurement budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Lucida Medical social profiles

Digital presence

Lucida Medical compliance and trust

Trust signal

Compliance1 record

Lucida Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucida Medical leadership team

Management profile

Number of profiles

Profiles10 records

Lucida Medical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucida Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucida Medical

What does Lucida Medical do?

Lucida Medical develops Pi (Prostate Intelligence), a CE-marked AI medical device software that analyzes prostate MRI scans to detect and diagnose clinically significant prostate cancer. The software performs automated prostate and lesion segmentation, generates risk scores, produces visual heat maps, and creates structured template reports that support radiologists and urologists in clinical decision-making across the prostate cancer diagnostic pathway.

Is Lucida Medical a public or private company?

Lucida Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lucida Medical founded?

Lucida Medical was founded in 2019. It employs 11 to 50 people.

Where is Lucida Medical based?

Lucida Medical is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Lucida Medical make money?

One revenue line is on record: AI Diagnostic Software Subscription (Pi SaaS).

Who are Lucida Medical's main competitors?

Direct peers on record are Avenda Health, ArteraAI, KOELIS and Quibim. Emerging players are Paige.AI, DeepHealth (RadNet) and Ibex Medical Analytics. Broad incumbents are Siemens Healthineers (AI-Rad Companion), GE Healthcare (Edison) and Philips (IntelliSpace AI).

Does Lucida Medical have an API?

No public API is recorded for Lucida Medical.

What industry is Lucida Medical in?

Lucida Medical's product category is AI Radiology Diagnostics Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaLucida Medical raises £8.7m to enable 'same day' cancer diagnosisLucida Medical, a Cambridge-based health tech company using AI to diagnose prostate cancer from MRI scans, has raised £8.7 million in its latest funding round with participation from IW Capital, XTX Ventures, and Macmillan Cancer Support. The company's AI software, which is approved for use in the UK and EU and deployed across 15 NHS hospitals, addresses a 30 per cent shortfall in clinical radiologists that could rise to 40 per cent by 2028. The funding will be used to secure FDA approval in the US and expand the platform to additional cancer types beyond prostate cancer.IwcapitalIW Capital leads an £8.7m investment round in Lucida Medical to power ‘same day’ cancer diagnosisIW Capital has led an £8.7 million investment round in Lucida Medical, a healthcare company focused on cancer diagnostics. The funding aims to support the development of 'same day' cancer diagnosis technology.Medical Device NetworkLucida Medical raises $11.4m to advance AI prostate cancer diagnosticUK-based Lucida Medical has raised \u00a38.7m ($11.4m) in funding led by VC firm IW Capital, with participation from existing investors XTX Ventures and Macmillan Cancer Support, to advance its AI-based prostate cancer diagnostic software. The Prostate Intelligence (Pi) platform, currently in pilot at 15 NHS sites including Leeds Teaching Hospitals NHS Trust, is designed to assist clinicians in identifying prostate cancer from MRI scans, addressing a 30% shortfall in UK radiologists and rising cancer imaging volumes. The company plans to use the funds for a future FDA regulatory submission and expansion into additional cancer types.UKTNAI diagnostic startup raises £9m in Macmillan-backed roundLucida Medical, a Cambridge-based AI startup, has raised £8.7 million in a funding round led by IW Capital with participation from Macmillan Cancer Support and XTX Ventures. The company's AI diagnostic service supports clinicians in diagnosing prostate cancer from MRI scans and is already deployed across NHS hospitals, aiming to address rising cancer imaging demand and reduce diagnostic waiting times. The funding will enable Lucida Medical to accelerate deployment of its technology to more NHS Trusts, where currently few can confirm or rule out cancer within the 28-day target.LucidamedicalLucida MedicalCambridge-based healthtech company Lucida Medical has raised £8.7 million in a funding round led by UK venture capital firm IW Capital, with participation from existing investors XTX Ventures and Macmillan Cancer Support. The investment will support expansion of its AI-powered prostate cancer diagnostic platform, which is already CE-certified and deployed across 15 NHS hospitals, while also funding pursuit of US FDA approval and extension to additional cancer types. The funding comes as the UK faces a 30% shortfall in clinical radiologists, projected to rise to 40% by 2028, with only 55% of prostate cancer patients in England diagnosed before the cancer spread in 2024.LinkedInCureMetrix's cmAngio: First AI for Breast Arterial Calcification DetectionThe NHS is piloting Lucida Medical's AI tool, Pi, across 15 hospitals to enable same-day prostate cancer diagnoses by analyzing MRI scans. This initiative aims to reduce biopsy rates and improve early detection, potentially saving over 1,000 lives annually if the model is successful.Jersey Evening PostCharity backs platform using AI to detect prostate cancer casesMacmillan Cancer Support invested £350,100 in Lucida Medical's Pi platform, which uses AI to detect prostate cancer from MRI scans. The charity's second investment in its £3.5 million portfolio aims to reduce unnecessary biopsies and improve patient outcomes. Macmillan will support development through its Innovation Community.Med-Tech InnovationPi prostate cancer platform receives funding for expansionLucida Medical, the University of Cambridge, and Hampshire Hospitals NHS Foundation Trust have secured funding from Innovate UK to expand their Pi AI software platform for prostate cancer diagnosis. The £1 million programme aims to enhance active surveillance capabilities by combining MRI insights with clinical tests to improve accuracy and reduce invasiveness. This development supports the monitoring of over 50,000 annual UK diagnoses through precision medicine workflows.AuntMinnieEuropeLucida Medical teams with institutions to develop Pi platformLucida Medical, the University of Cambridge, and Hampshire Hospitals NHS Foundation Trust have received £1 million in funding from Innovate UK and the Office for Life Sciences to expand their Pi AI software platform for prostate cancer diagnosis. The project aims to enhance active surveillance capabilities by developing new datasets and training algorithms using historical patient data. Lucida Medical is scheduled to showcase the Pi platform at ECR 2024 in Vienna.